Used as a key intermediate in the synthesis of sodium channel inhibitors targeting voltage-gated sodium channels such as NaV1.7, which are implicated in neuropathic and chronic pain signaling in the central and peripheral nervous systems. Its structure facilitates selective inhibition of sodium channel opening, reducing aberrant neuronal excitation that causes pain without significantly affecting muscle or cardiac function, offering advantages over older inhibitors with higher side effect profiles.

In vitro and in vivo studies of derived compounds demonstrate potent and selective blockade, enhancing therapeutic potential for patients unresponsive to conventional analgesics. The trans stereochemistry improves metabolic stability and bioavailability, supporting better in vivo efficacy. It is also employed in structure-activity relationship (SAR) studies to optimize potency, selectivity, and safety for novel pain therapeutics currently under research and development.